

## 2'-Chloro-1-hydroxy-2-naphthanilide-4'-isothiocyanate — a New Cestodicidal Agent [1]

Harindra Singh, Satyavan Sharma, and R. N. Iyer

Division of Medicinal Chemistry

and

J. C. Katiyar and A. B. Sen


Division of Parasitology, Central Drug Research Institute, Lucknow-226001, India

Z. Naturforsch. 33 c, 447–448 (1978);  
received March 9, 1978

Cestodicidal Agent, *Hymenolepis nana*

2'-Chloro-1-hydroxy-2-naphthanilide-4'-isothiocyanate (**4**) has been synthesized as the structural analogue of yomesan (**1**) and was found to be active against experimental dwarf tapeworm *Hymenolepis nana* infection in rats at an oral dose of 7.5 mg/kg.

Despite the wide prevalence of cestode infections [2, 3], its chemotherapy has remained surprisingly backward during the past decade. Among the various compounds claimed to be effective against cestode parasites, 2',5-dichloro-4'-nitrosalicylanilide (**1**, yomesan) has been reported to possess high taenicial activity in a number of hosts [4] including humans [5]. In continuation of our earlier efforts [6, 7] in this laboratory to develop a better cestodicidal agent than **1**, a series of substituted-1-hydroxy-2-naphthanilides [9] were synthesized of which 2'-Chloro-1-hydroxy-2-naphthanilide-4'-isothiocyanate (**4**) was found to be highly effective



against *Hymenolepis nana* infection in rats. This communication reports the synthesis and cestodicidal activity of **4**.

1-Hydroxy-2-(2-chloro-4-nitro)naphthanilide (**2**), required as the starting material, was synthesized by treating 1-hydroxy-2-naphthoic acid with 2-chloro-4-nitro aniline in presence of phosphorus trichloride [10]. Hydrogenation of **2** using Raney-nickel as catalyst gave 82% yield of 1-hydroxy-2-(4-

amino-2-chloro) naphthanilide (**3**) [11]. A solution of thiophosgene (1 ml) in chloroform (100 ml) was added dropwise to a stirred solution of **3** (3.2 g) in acetic acid (50 ml) and 4 N HCl (15 ml) and the reaction mixture stirred for 6 h at room temperature. Organic layer was separated, washed with water, dried ( $\text{Na}_2\text{SO}_4$ ) and the residue, obtained on removal of solvent, was crystallised from acetone to give 3 g (85%) of **4** m.p.  $180^\circ$ ,  $\nu_{\text{max}}$  (KBr)  $\text{cm}^{-1}$  3400 (OH), 2050 (NCS), 1640 (CONH). Anal. Calcd for  $\text{C}_{18}\text{H}_{11}\text{ClN}_2\text{O}_2\text{S}$ : C, 60.93; H, 3.10; N, 7.89; Found: C, 60.83; H, 3.30; N, 7.98%.

The cestodicidal testing of **4** was carried out against experimental *H. nana* infection in rats using the technique of Steward [12] with slight modifications. Newly weaned male rats of University of Freiburg strain were infected by feeding them with 200 viable ova of *H. nana*. On day 15, after intubation of viable ova, rats which were found positive of *H. nana* ova in their faeces were treated after being starved overnight. Initially a single dose of 250 mg/kg of the compound was given orally to 3 animals and 3 were kept as control. All animals including the controls were again starved overnight before being sacrificed on day 3 post-treatment. The small intestine from individual animal was removed separately, washed and the worms collected and scored. Compound bringing down the worm load to 0–10% of the control was considered to be active in this test.

During the first investigation on the efficacy of **4** against *H. nana* in rats, **4** was given orally at dosages 250, 100, 50 and 10 mg/kg. The minimum effective dose giving 100% clearance of worm-load was found to be 7.5 mg/kg. In simultaneous controlled trials in rats, **4** exhibited  $\text{ED}_{100}$  and  $\text{ED}_{50}$  at 5 and 1.74 mg/kg given orally. Parallel experiments with yomesan (**1**) showed  $\text{ED}_{100}$  and  $\text{ED}_{50}$  at 50 and 14.5 mg/kg respectively. The relative potency of **4** with respect to **1** is calculated to be 8.3 (Table I).

Cestodicidal activity tests in mice infected with *H. nana* showed that **4** could achieve 100% removal of the worms at a dose of 14 mg/kg in comparison to 280 mg/kg dose of **1** for same order of activity.

The toxicity experiments carried on the normal and infected rats were highly encouraging. A single oral dose of 5 g/kg was tolerated well by normal rats without any mortality. Similarly, the young infected rats tolerated 1 g/kg of the compound (higher

Request for reprints should be sent to Dr. R. N. Iyer, Medicinal Chemistry Division, C.D.R.I., Lucknow-226001, India.



Dieses Werk wurde im Jahr 2013 vom Verlag Zeitschrift für Naturforschung in Zusammenarbeit mit der Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. digitalisiert und unter folgender Lizenz veröffentlicht: Creative Commons Namensnennung-Keine Bearbeitung 3.0 Deutschland Lizenz.

Zum 01.01.2015 ist eine Anpassung der Lizenzbedingungen (Entfall der Creative Commons Lizenzbedingung „Keine Bearbeitung“) beabsichtigt, um eine Nachnutzung auch im Rahmen zukünftiger wissenschaftlicher Nutzungsformen zu ermöglichen.

This work has been digitalized and published in 2013 by Verlag Zeitschrift für Naturforschung in cooperation with the Max Planck Society for the Advancement of Science under a Creative Commons Attribution-NoDerivs 3.0 Germany License.

On 01.01.2015 it is planned to change the License Conditions (the removal of the Creative Commons License condition "no derivative works"). This is to allow reuse in the area of future scientific usage.

Table I. Comparative Efficacy of 4 and yomesan. (Probit Analysis — M. L. Method)

	4				Yomesan				
Dose (mg/kg)	5	2.5	1.75	1.25	50	25	17.5	12.5	8.75
No. of animals treated	6	4	5	6	4	5	7	9	5
No. of animals cleared	6	3	3	1	4	4	5	3	1
% Response	100	75	60	16.7	100	80	71.4	33.3	20
ED <sub>50</sub>		1.74					14.5		
Fiducial limits		1.11—2.64				9.3—21.2			

Relative potency of 4 with respect to yomesan with fiducial limit — 8.3 (5.2—13.5).

dosages were not tried in view of the very low ED<sub>50</sub>). The compound was found to be equally safe in mice, mastomys and dogs.

In further tests carried against *Hymenolepis diminuta* in rats and *Taenia* sp. in dogs, 4 proved to possess marked activity. The compound is currently in the advanced pharmacological and chronic

toxicity studies in rats and monkeys in our laboratory.

The authors thank Dr. Nitya Anand for his interest and encouragement in the work and Messers T. K. Chowdhary and V. K. Agrawal for technical assistance.

- [1] Communication No. 2250 from Central Drug Research Institute, Lucknow.
- [2] N. R. Stoll, *J. Parasit.* **33**, 18 (1947).
- [3] I. Carneri and G. Vita, *Chemotherapy of Helminthiasis*, Vol. 1, p. 150 (Ed. F. Hawking), Pergamon Press, Oxford 1973.
- [4] O. D. Standen, *Experimental Chemotherapy*, Vol. 1, p. 736 (Eds. R. J. Schnitzer and F. Hawking), Academic Press, New York 1963.
- [5] E. L. Lloyd, *Practitioner* **187**, 679 (1961).
- [6] H. Singh, S. Sharma, A. K. Singh, R. N. Iyer, P. Govil, J. C. Katiyar, and A. B. Sen, *Ind. J. Exp. Biol.* **14**, 332 (1976).
- [7] H. Singh, S. Sharma, and R. N. Iyer, *Indian J. Chem.* **15 B**, 73 (1977).
- [8] H. Singh, A. K. Singh, S. Sharma, R. N. Iyer, and O. P. Srivastava, *J. Med. Chem.* **20**, 826 (1977).
- [9] Indian Patent application No. 2120/cal/75.
- [10] C. B. Roth and F. W. H. Mueller, *German Pat.* 1 120 274 (1961); *Chem. Abstr.* **57**, 11 348 (1962).
- [11] G. H. Klinger, *U.S. Pat.* 3 112 198 (1963); *Chem. Abstr.* **60**, 10 848 (1964).
- [12] J. S. Steward, *Parasit* **45**, 225 (1955).